ETNB - 89bio expects to initiate Phase 2b NASH trial in 1H21

89bio (ETNB) provided a corporate update, including its roadmap for advancing BIO89-100 in 2021.The Company is steadily executing across all clinical development program for BIO89-100, a potentially best-in-class FGF21 analog engineered to achieve superior efficacy, optimal dosing convenience, as well as favorable safety and tolerability.Topline data from recently initiated NASH paired-biopsy, open-label histology cohort expected by year end 2021.Also, Phase 2b NASH trial as part of a potential Phase 2b/3 program expected to initiate in 1H21.Topline data from BIO89-100’s Phase 2 SHTG trial expected in 2H21.

For further details see:

89bio expects to initiate Phase 2b NASH trial in 1H21